Phenotypes associated with this allele

• Allele Symbol: Picalm^tm1.1Tmae
• Allele Name: targeted mutation 1.1, Takahiro Maeda
• Allele ID: MGI:5636370
• Summary: 5 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
cn1	Gt(ROSA)26Sor^tm1(cre/ERT2)Thl/0 Picalm^tm1.1Tmae/Picalm^tm1.1Tmae	involves: 129 * C57BL/6 * SJL	MGI:5639333
cn2	Jak2^tm1.2Ble/Jak2^+ Picalm^tm1.1Tmae/Picalm^tm1.1Tmae Commd10^Tg(Vav1-icre)A2Kio/Commd10^+	involves: 129S6/SvEvTac * C57BL/6 * C57BL/10 * CBA * SJL	MGI:5640744
cn3	Picalm^tm1.1Tmae/Picalm^tm1.1Tmae Commd10^Tg(Vav1-icre)A2Kio/Commd10^+	involves: 129S6/SvEvTac * C57BL/6 * C57BL/10 * CBA * SJL	MGI:5640745
cn4	Jak2^tm1.2Ble/Jak2^+ Picalm^tm1.1Tmae/Picalm^+ Commd10^Tg(Vav1-icre)A2Kio/Commd10^+	involves: 129S6/SvEvTac * C57BL/6 * C57BL/10 * CBA * SJL	MGI:5640746
cn5	Picalm^tm1.1Tmae/Picalm^tm1.1Tmae Tg(Mx1-cre)1Cgn/0	involves: C57BL/6 * CBA * SJL	MGI:5639318

Genotype
MGI:5639333

cn1

• Allelic Composition: Gt(ROSA)26Sor^{tm1(cre/ERT2)Thl}/0; Picalm^tm1.1Tmae/Picalm^tm1.1Tmae
• Genetic Background: involves: 129 * C57BL/6 * SJL

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

hematopoietic system

abnormal erythropoiesis ( J:220728 )

• inefficient erythroid differentiation in the spleen following tamoxifen treatment

hypochromic microcytic anemia ( J:220728 )

• mice develop microcytic and hypochromic anemia following tamoxifen treatment

integument

diluted coat color ( J:220728 )

• gray coat color

pigmentation

diluted coat color ( J:220728 )

• gray coat color

Genotype
MGI:5640744

cn2

• Allelic Composition: Jak2^tm1.2Ble/Jak2⁺; Picalm^tm1.1Tmae/Picalm^tm1.1Tmae; Commd10^{Tg(Vav1-icre)A2Kio}/Commd10⁺
• Genetic Background: involves: 129S6/SvEvTac * C57BL/6 * C57BL/10 * CBA * SJL

hematopoietic system

hypochromic microcytic anemia ( J:220728 )

decreased erythrocyte cell number ( J:220728 )

• decreased numbers of mature erythrocytes

decreased hematocrit ( J:220728 )

decreased hemoglobin content ( J:220728 )

decreased mean corpuscular hemoglobin ( J:220728 )

decreased mean corpuscular volume ( J:220728 )

decreased CD4-positive, alpha-beta T cell number ( J:220728 )

• decreased numbers of CD4+ T cells

decreased CD8-positive, alpha-beta T cell number ( J:220728 )

• decreased numbers of CD8+ T cells

reticulocytosis ( J:220728 )

• elevated reticulocyte counts

homeostasis/metabolism

abnormal iron homeostasis ( J:220728 )

• transferrin/transferrin receptor endocytic rate is decreased as compared to wild-type

immune system

decreased CD4-positive, alpha-beta T cell number ( J:220728 )

• decreased numbers of CD4+ T cells

decreased CD8-positive, alpha-beta T cell number ( J:220728 )

• decreased numbers of CD8+ T cells

Genotype
MGI:5640745

cn3

• Allelic Composition: Picalm^tm1.1Tmae/Picalm^tm1.1Tmae; Commd10^{Tg(Vav1-icre)A2Kio}/Commd10⁺
• Genetic Background: involves: 129S6/SvEvTac * C57BL/6 * C57BL/10 * CBA * SJL

hematopoietic system

microcytic anemia ( J:220728 )

decreased erythrocyte cell number ( J:220728 )

• decreased numbers of mature erythrocytes

decreased mean corpuscular hemoglobin ( J:220728 )

decreased mean corpuscular volume ( J:220728 )

decreased CD4-positive, alpha-beta T cell number ( J:220728 )

• decreased numbers of CD4+ T cells

decreased CD8-positive, alpha-beta T cell number ( J:220728 )

• decreased numbers of CD8+ T cells

reticulocytosis ( J:220728 )

• elevated reticulocyte counts

homeostasis/metabolism

increased circulating erythropoietin level ( J:220728 )

• high levels of serum erythropoietin

abnormal iron homeostasis ( J:220728 )

• transferrin/transferrin receptor endocytic rate is decreased as compared to wild-type

immune system

decreased CD4-positive, alpha-beta T cell number ( J:220728 )

• decreased numbers of CD4+ T cells

decreased CD8-positive, alpha-beta T cell number ( J:220728 )

• decreased numbers of CD8+ T cells

Genotype
MGI:5640746

cn4

• Allelic Composition: Jak2^tm1.2Ble/Jak2⁺; Picalm^tm1.1Tmae/Picalm⁺; Commd10^{Tg(Vav1-icre)A2Kio}/Commd10⁺
• Genetic Background: involves: 129S6/SvEvTac * C57BL/6 * C57BL/10 * CBA * SJL

hematopoietic system

increased erythrocyte cell number ( J:220728 )

• increased red blood cell counts

increased hematocrit ( J:220728 )

• high hematocrit

increased hemoglobin content ( J:220728 )

decreased mean corpuscular hemoglobin ( J:220728 )

decreased mean corpuscular volume ( J:220728 )

thrombocytosis ( J:220728 )

• mild thrombocytosis

reticulocytosis ( J:220728 )

• elevated reticulocyte counts

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
polycythemia vera		DOID:8997	OMIM:263300	J:220728

Genotype
MGI:5639318

cn5

• Allelic Composition: Picalm^tm1.1Tmae/Picalm^tm1.1Tmae; Tg(Mx1-cre)1Cgn/0
• Genetic Background: involves: C57BL/6 * CBA * SJL

hematopoietic system

enlarged spleen ( J:220728 )

hypochromic microcytic anemia ( J:220728 )

• mice develop microcytic and hypochromic anemia following polyinosinicpolycytidylic acid (pIpC) treatment

impaired hematopoiesis ( J:220728 )

decreased erythroblast number ( J:220728 )

• decreased number of mature (R4) erythroblasts in the spleen in proportion to number of R2 erythroblasts

increased erythroblast number ( J:220728 )

• increased numbers of immature (R2) erythroblasts in the spleen in proportion to number of R4 erythroblasts

abnormal erythrocyte morphology ( J:220728 )

• variation in red blood cell size and shape

abnormal erythropoiesis ( J:220728 )

• impaired transition of stage III (poly-chromatophilic) to stage IV (ortho-chromatophilic) erythroblasts

• increase in erythroblast apoptosis

• decrease in number of fully-formed clathrin coated pits in erythroblast

decreased erythrocyte cell number ( J:220728 )

• reduced numbers of red blood cells in peripheral blood following pIpC treatment

decreased hematocrit ( J:220728 )

• reduced hematocrit levels in peripheral blood following pIpC treatment

decreased hemoglobin content ( J:220728 )

• reduced hemoglobin levels in peripheral blood following pIpC treatment

• reticulocytes have a low hemoglobin content

decreased mean corpuscular hemoglobin ( J:220728 )

• decreased mean corpuscular volume following pIpC treatment

decreased mean corpuscular volume ( J:220728 )

• decreased mean corpuscular hemoglobin following pIpC treatment

increased red blood cell distribution width ( J:220728 )

• increased red cell distribution width in peripheral blood following pIpC treatment

decreased CD4-positive, alpha-beta T cell number ( J:220728 )

• decreased numbers of CD4+ T cells beginning 3 months after pIpC treatment

decreased CD8-positive, alpha-beta T cell number ( J:220728 )

• decreased numbers of CD8+ T cells beginning 5 months after pIpC treatment

reticulocytosis ( J:220728 )

• elevated reticulocyte counts

• increase in percentage of immature reticulocyte fraction

homeostasis/metabolism

increased circulating erythropoietin level ( J:220728 )

• high serum erythropoietin levels beginning 2 months after pIpC treatment

abnormal iron homeostasis ( J:220728 )

• increased amounts of surface-bound transferrin in relation to internalized transferrin on erythroblasts as compaired to wild-type

• transferrin receptor endocytosis is 25% as efficient as wild-type

increased circulating iron level ( J:220728 )

• elevated serum iron levels

immune system

enlarged spleen ( J:220728 )

decreased CD4-positive, alpha-beta T cell number ( J:220728 )

• decreased numbers of CD4+ T cells beginning 3 months after pIpC treatment

decreased CD8-positive, alpha-beta T cell number ( J:220728 )

• decreased numbers of CD8+ T cells beginning 5 months after pIpC treatment

growth/size/body

enlarged spleen ( J:220728 )